The Managed Access Program (MAP) was run in Italy from June 2018 to December 2019 to provide D + T in adjuvant settings to patients with BRAF V600 stage III melanoma following complete tumor resection and without alternative treatment options; roughly 550 patients were involved. The gene discussed is BRAF; the disease is melanoma.